🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for DLBCL

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Lenalidomide combined with G-CHOP (LO CHOP) RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL NCT06674096Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: RLC-CRCHOP Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site📍 Milan Incyte Biosciences Italy S.r.l Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL NCT06760039Phase 1, Phase 210 sites📍 Fuzhou📍 Lanzhou📍 Guangzhou Sun Yat-sen University · Tests: R-CMOP Regimen, R-CHOP Regimen Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites📍 Anchorage📍 Clovis📍 Fullerton Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites📍 Seville📍 Zaragoza📍 Palma de Mallorca Grupo Español de Linfomas y Transplante Autólogo de Médula … · Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714Phase 1, Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Lenalidomide, Rituximab, Etoposide, Doxorubicin, Vincristine Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) NCT06526065n/a1 site📍 Göttingen University Medical Center Goettingen · Tests: no intervention Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation NCT06793410Phase 25 sites📍 Lund📍 Stockholm📍 Uppsala Vastra Gotaland Region · Tests: Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9® The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk NCT05018520Phase 31 site📍 Shanghai Ruijin Hospital · Tests: Six Courses of R-CHOP Plus Two Courses of Rituximab, Four Courses of R-CHOP Plus Four Courses of Rituximab Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites📍 Graz📍 Innsbruck📍 Linz Miltenyi Biomedicine GmbH · Tests: MB-CART2019.1, Standard of Care Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program NCT06782789n/a11 sites📍 Bologna📍 Caserta📍 Catania IRCCS Azienda Ospedaliero-Universitaria di Bologna A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma NCT06683885Phase 1, Phase 21 site📍 Zhengzhou Mingzhi Zhang · Tests: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients NCT06569485Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Trilaciclib+R-CHOP A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site📍 West Valley City Lantern Pharma Inc. · Tests: LP-284 Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL NCT07749365Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL NCT06693830NA1 site📍 New York Hua-Jay J Cherng, MD · Tests: Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment Pola-ZR2P in Previously Untreated DLBCL NCT06664411Phase 21 site📍 Beijing Navy General Hospital, Beijing · Tests: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848Phase 11 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Vancomycin 125mg, Radiation Therapy, CAR-T Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation NCT07499271Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: POLA-R-CHP, Orelabrutinib Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma NCT07084662Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Xinlikang capsules, mimic capsules Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL NCT07778212NA2 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Orelabrutinib Combined with Pola-R-CHP Regimen
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy